Location via proxy:   [ UP ]  
[Report a bug]   [Manage cookies]                
Scribd Logo
Upload

Welcome to Scribd!

  • 583 views

    DS Erythropoietin

    Uploaded by

    jessicamays
    Erythropoietin, also known as Epoetin Alfa, is a recombinant human erythropoietin used to treat anemia related to chronic renal failure, anemia due to HIV/AIDS medication, and anemia from chemotherapy. It is administered subcutaneously twice per week at a dose of 400 units. Common side effects include hypertension, deep vein thrombosis, fatigue, headache, nausea, and skin reactions at the injection site. Nurses monitor patients for side effects and lab values like hemoglobin and iron levels during treatment.

    Copyright:

    Attribution Non-Commercial (BY-NC)
    Download as DOC, PDF, TXT or read online from Scribd

    DS Erythropoietin

    Uploaded by

    jessicamays
    583 views2 pages
    Erythropoietin, also known as Epoetin Alfa, is a recombinant human erythropoietin used to treat anemia related to chronic renal failure, anemia due to HIV/AIDS medication, and anemia from chemotherapy. It is administered subcutaneously twice per week at a dose of 400 units. Common side effects include hypertension, deep vein thrombosis, fatigue, headache, nausea, and skin reactions at the injection site. Nurses monitor patients for side effects and lab values like hemoglobin and iron levels during treatment.

    Original Title

    DS-erythropoietin

    Copyright

    © Attribution Non-Commercial (BY-NC)

    Available Formats

    DOC, PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Erythropoietin, also known as Epoetin Alfa, is a recombinant human erythropoietin used to treat anemia related to chronic renal failure, anemia due to HIV/AIDS medication, and anemia from chemotherapy. It is administered subcutaneously twice per week at a dose of 400 units. Common side effects include hypertension, deep vein thrombosis, fatigue, headache, nausea, and skin reactions at the injection site. Nurses monitor patients for side effects and lab values like hemoglobin and iron levels during treatment.

    Copyright:

    Attribution Non-Commercial (BY-NC)
    Download as DOC, PDF, TXT or read online from Scribd
    Download as doc, pdf, or txt
    583 views2 pages

    DS Erythropoietin

    Uploaded by

    jessicamays
    Erythropoietin, also known as Epoetin Alfa, is a recombinant human erythropoietin used to treat anemia related to chronic renal failure, anemia due to HIV/AIDS medication, and anemia from chemotherapy. It is administered subcutaneously twice per week at a dose of 400 units. Common side effects include hypertension, deep vein thrombosis, fatigue, headache, nausea, and skin reactions at the injection site. Nurses monitor patients for side effects and lab values like hemoglobin and iron levels during treatment.

    Copyright:

    Attribution Non-Commercial (BY-NC)
    Download as DOC, PDF, TXT or read online from Scribd
    Download as doc, pdf, or txt
    of 2

    Erythropoietin, Epoetin Alfa

    Generic Name

    Brand Name Drug Classification Ordered Dose Indications

    Epogen, procrit Recombinant human erythropoietin 400 units SQ 2x in one week Treatment of anemia related to chronic renal failure (CRF) Anemia related to zidovudine therapy in HIV-infected patients Anemia due to chemotherapy in patients with metastatic nonmyeloid malignancies

    Contraindications

    Contraindicated with Hypersensitivity to mammalian cellderived products or human albumin; uncontrolled hypertension. Cardiovascular: Hypertension; deep venous thrombosis CNS: Fatigue; dizziness, insomnia; headache; anxiety, paresthesia Dermatologic: Pruritus; rash

    Adverse Effects

    GI: Nausea; constipation; vomiting; diarrhea; dyspepsia Genitourinary: UTI Local: Skin reaction at injection site Respiratory: shortness of breath

    Nursing Responsibilities

    Assess clients allergy to mammalian cellderived products or human albumin; uncontrolled hypertension Determine Hgb twice a week in CRF patients and once weekly in zidovudine-treated HIV patients until Hgb has stabilized and the maintenance dose has been established. Then, determine Hgb weekly for at least 4 wk, until it has been determined that Hgb has stabilized in response to the dose change. Then, monitor at regular intervals. Closely monitor BP during therapy. Monitor iron stores, including transferrin saturation and serum ferritin, renal function, fluid and electrolyte balance, CBC with differential and platelet count, and serum chemistry regularly. In CRF patients, after any dose adjustment, determine the Hgb twice

    weekly for at least 2 to 6 wk until it is determined that the Hgb has stabilized. Then monitor at regular intervals.

    You might also like